Cannabis and Blood-Cell Gene Expression: What an mRNA Finding Does Not Prove

A change in gene expression in blood lymphocytes is not a diagnosis of brain injury, psychosis, or driving impairment. A small controlled cannabis study demonstrates why a biological response must remain connected to its actual tissue and measured endpoint.

The experiment and specimen

Smith and colleagues examined a 24-person subset of a cannabis study. Participants who regularly used cannabis smoked cigarettes containing different THC concentrations or placebo. Researchers separated lymphocytes from blood and measured messenger RNA for cannabinoid receptors, methylation-related enzymes, and other markers.

Whole-blood THC was a separate measurement. The study therefore contained both an exposure measure and cellular-expression outcomes; they were not interchangeable versions of the same test.

Positive findings and important null results

The higher-potency group showed increases in selected mRNAs compared with placebo at particular times, including CB2 and DNMT3A at four hours. However, combining the two THC groups removed statistical significance for the differences from placebo. Changes in blood THC were not related to changes in mRNA. The active groups also did not differ significantly in postsmoking blood THC concentrations.

These details limit a simple story in which cigarette potency determines blood concentration, which then determines every cellular response. Baseline differences and the small subgroup sizes also complicate interpretation.

Expression is not the same as lasting epigenetic injury

Measuring mRNA for a methylation-related enzyme does not itself demonstrate a permanent change in DNA methylation, altered protein function, or damage in another organ. Lymphocytes are peripheral immune cells, not sampled brain neurons. A hypothesis about a pathway linking exposure and disease requires further evidence at each step.

Using the paper in an individual dispute

An expert should specify the marker, time point, comparison group, and whether the finding persisted across analyses. The paper did not establish that its participants developed schizophrenia, nor validate these mRNAs as individual impairment tests. Those are different endpoints from the ones studied.

The appropriate use is mechanistic context with explicit limitations. It cannot replace clinical diagnosis, incident-specific behavior, or a validated explanation connecting a person’s measured result to the conclusion offered.

Related evidence

See our related analysis of toxicology evidence and its limits.

Primary research

Changes in Expression of DNA-Methyltransferase and Cannabinoid Receptor mRNAs in Blood Lymphocytes After Acute Cannabis Smoking. Frontiers in Psychiatry, 2022. DOI: 10.3389/fpsyt.2022.887700.